Regulatory mechanisms of major depressive disorder risk variants

S Li, Y Li, X Li, J Liu, Y Huo, J Wang, Z Liu, M Li… - Molecular …, 2020 - nature.com
Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders and a
leading cause of disability worldwide. Though recent genome-wide association studies …

The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice

Z Li, Y Zhang, Z Wang, J Chen, J Fan, Y Guan… - Journal of psychiatric …, 2013 - Elsevier
BACKGROUND: Although genetic variants may play a key role in development of treatment-
resistant depression (TRD), relevant research is scarce. METHODS: To examine whether …

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

M Kato, A Serretti - Molecular psychiatry, 2010 - nature.com
This systematic review summarizes pharmacogenetic studies on antidepressant response
and side effects. Out of the 17 genes we reviewed, 8 genes were entered into the meta …

From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment

C Fabbri, S Porcelli, A Serretti - The Canadian Journal of …, 2014 - journals.sagepub.com
Objective: Major depressive disorder is the most common psychiatric disorder, worldwide,
yet response and remission rates are still unsatisfactory. The identification of genetic …

Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies

Gendep Investigators… - American Journal of …, 2013 - Am Psychiatric Assoc
Objective Indirect evidence suggests that common genetic variation contributes to individual
differences in antidepressant efficacy among individuals with major depressive disorder, but …

Genetic variants in major depressive disorder: from pathophysiology to therapy

X Gonda, P Petschner, N Eszlari, D Baksa… - Pharmacology & …, 2019 - Elsevier
In spite of promising preclinical results there is a decreasing number of new registered
medications in major depression. The main reason behind this fact is the lack of confirmation …

Pharmacogenetics in major depression: a comprehensive meta-analysis

T Niitsu, C Fabbri, F Bentini, A Serretti - Progress in Neuro …, 2013 - Elsevier
A number of candidate gene studies focused on major depression (MD) and antidepressant
(AD) efficacy have been carried out, but results mainly remain inconclusive. We performed a …

[HTML][HTML] The potential of polygenic risk scores to predict antidepressant treatment response in major depression: a systematic review

JJ Meerman, SE Ter Hark, JGE Janzing… - Journal of Affective …, 2022 - Elsevier
Background Understanding the genetic underpinnings of antidepressant treatment response
in unipolar major depressive disorder (MDD) can be useful in identifying patients at risk for …

The Australian Genetics of Depression Study: new risk loci and dissecting heterogeneity between subtypes

BL Mitchell, AI Campos, DC Whiteman, CM Olsen… - Biological …, 2022 - Elsevier
Background Major depressive disorder (MDD) is a common and highly heterogeneous
psychiatric disorder, but little is known about the genetic characterization of this …

Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder

E Lin, PS Chen, HH Chang, PW Gean, HC Tsai… - Progress in Neuro …, 2009 - Elsevier
BACKGROUND: Four serotonin-related genes including guanine nucleotide binding protein
beta polypeptide 3 (GNB3), 5-hydroxytryptamine receptor 1A (HTR1A; serotonin receptor …